CAS: 16075-42-6; 2-Amino-4-(Trifluoromethyl)Pyrimidine

相似化合物

1780891-13-5 5734-63-4 197305-97-8

上下游产品

CAS号935534-47-7 4-三氟甲基-5-溴-2-嘧啶胺 | CAS号73183-34-3 双戊酰二硼 | CAS号59938-06-6 (E)-4-乙氧基-1,1,1... | CAS号113-00-8 guanidine | CAS号50-01-1 盐酸胍 | CAS号593-85-1 碳酸胍 | CAS号149771-09-5 2-氨基-4-(三氟甲基)嘧啶... | CAS号149771-23-3 2-氨基-4-三氟甲基嘧啶-5-甲酸 | CAS号1045861-30-0 2-氨基-4-(三氟甲基)嘧啶... | CAS号375857-65-1 3-溴-7-(三氟甲基)咪唑并... | CAS号944401-58-5 2-氨基-4-三氟甲基嘧啶-5... | CAS号935534-47-7 4-三氟甲基-5-溴-2-嘧啶胺

2-氨基-4-三氟甲基嘧啶-5-羧酸乙酯置于氢氧化钾体系中,用 乙醇 用作溶剂,化学反应 11.0H,反应生成4-三氟甲基-2-氨基嘧啶
参考文献:Sansebastiano; Mosti; Menozzi,Il Farmaco,1993,Vol. 48,# 3,P. 335-355
标题:Sansebastiano; Mosti; Menozzi,Il Farmaco,1993,Vol. 48,# 3,P. 335-355

专利信息

专利号:WO-2023091726-A1
优先权日:2021-11-18
标题:Inhibitors of cyclin‑dependent kinase 12 (cdk12)
发明人：BENOIT GUILLAUME; CARULLI JOHN; CHEN FEI; CHUAQUI CLAUDIO; CIBLAT STEPHANE; COOPER ELLIOT; DAGENAIS ROBIN; HU SHANHU; KABRO ANZHELIKA; LAPLACA DEREK; MARINEAU JASON; MOEBIUS DAVID; MOON DIANE; SOLODININ ANDREI; WHITMORE KENNETH
权利人:SYROS PHARMACEUTICALS INC
摘要:The present invention provides chemical compounds that inhibit one or more families of kinases (e.g., serine/threonine kinases, including one or more of the families of CDK proteins, and in particular, CDK12). More specifically, the present invention provides CDK12 inhibitors, of formula (I), pharmaceutically acceptable salts and isotopically labeled derivatives thereof, pharmaceutical compositions containing the compounds/inhibitors, and methods of their synthesis and use in treating proliferative diseases (e.g., a bladder cancer, a breast cancer, Ewing's sarcoma, a gastric cancer, a gastrointestinal cancer, a hematologic cancer, a lung cancer (e.g., small cell lung cancer (SCLC)), an ovarian cancer (e.g., a high grade serous ovarian cancer), a pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), a brain cancer (e.g., glioblastoma), or a prostate cancer), alone or in combination with a second therapeutic agent. The proliferative disease can be a cancer, benign neoplasm, or pathologic angiogenesis, and any of the therapeutic methods or uses described herein can include a step of diagnosing the patient's disease. In other embodiments of the invention, the compositions described herein (e.g., the compounds, pharmaceutical compositions, and kits containing them) are used for the treatment of myotonic dystrophy (type 1 or type 2).

专利号:CA-2718858-A1
优先权日:2008-03-20
标题:Selective synthesis of substituted pyrimidines